{"id":64687,"date":"2026-01-20T17:22:03","date_gmt":"2026-01-20T11:52:03","guid":{"rendered":"https:\/\/www.nextias.com\/ca\/?p=64687"},"modified":"2026-01-20T23:00:47","modified_gmt":"2026-01-20T17:30:47","slug":"patents-public-health-india","status":"publish","type":"post","link":"https:\/\/www.nextias.com\/ca\/editorial-analysis\/20-01-2026\/patents-public-health-india","title":{"rendered":"Patent Rights &amp; Public Health: What are India\u2019s Options?"},"content":{"rendered":"\n<p><strong>Syllabus: GS2\/Issues Related To Health; GS3\/ S&amp;T<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Context<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India stands at a critical intersection between the enforcement of <strong>Intellectual Property Rights (IPRs)<\/strong> and the fulfillment of its <strong>public health obligations.<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Public Health and Patent Rights in India<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Public health obligations<\/strong> demand <strong>equitable access<\/strong> to affordable medicines and technologies, while <strong>patents<\/strong> are designed <strong>to promote innovation and encourage investment in research<\/strong>.<\/li>\n\n\n\n<li>It is essential for ensuring that Intellectual Property (IP) laws serve both innovation and humanity, as <strong>India (Bharat) <\/strong>serves as the \u2018<strong>pharmacy of the Global South\u2019<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Constitutional and Institutional Framework<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Article 21 of the Constitution:<\/strong> It guarantees the <strong>right to life<\/strong>, a right that the Supreme Court has consistently interpreted to <strong>include the right to health<\/strong>.<\/li>\n\n\n\n<li><strong>World Trade Organization (WTO):<\/strong> India is a <strong>member of the WTO<\/strong> and bound by the <strong>Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement<\/strong>.\n<ul class=\"wp-block-list\">\n<li>It mandates the protection of intellectual property and allows <strong>flexibilities<\/strong> like member states have the right to protect public health and promote access to medicines for all (<strong>Doha Declaration on TRIPS and Public Health, 2001).<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>The Patents Act, 1970<\/strong> and its <strong>amendment in 2005<\/strong> provides the legal backbone for India\u2019s patent system.\n<ul class=\"wp-block-list\">\n<li>It embeds <strong>safeguards<\/strong> to prevent abuse of monopoly rights while it protects genuine inventions.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>TRIPS Flexibilities and India\u2019s Strategic Use<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India\u2019s patent regime utilizes TRIPS-compliant flexibilities to promote health equity. These include:\n<ul class=\"wp-block-list\">\n<li><strong>Parallel imports<\/strong>: Allowing importation of patented products marketed abroad at lower prices.<\/li>\n\n\n\n<li><strong>Compulsory licenses for export (Section 92A)<\/strong>: Permitting production of patented drugs for export to countries with insufficient manufacturing capacity.<\/li>\n\n\n\n<li><strong>Price control mechanisms<\/strong>: Ensuring affordability through the <strong>National Pharmaceutical Pricing Authority (NPPA)<\/strong>.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Such measures have earned India recognition as a <strong>model for developing nations<\/strong>, balancing TRIPS obligations with social justice.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Concerns &amp; Issues Surrounding Public Health and Patent Rights in India<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Evergreening Challenge: <\/strong>Evergreening in the pharmaceutical and agricultural sectors <strong>undermines equitable access to essential goods.<\/strong>\n<ul class=\"wp-block-list\">\n<li>Pharmaceutical companies from the Global North often attempt to \u2018<strong>evergreen\u2019<\/strong> patents by making minor modifications such as new salts, formulations, or dosage forms without significant therapeutic advancement.\n<ul class=\"wp-block-list\">\n<li>It restricts competition, delays generic entry, and inflates drug prices.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Conflict Between Innovation and Access:<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>For innovators<\/strong>, patents represent recognition of intellectual effort and a means to recover R&amp;D investments.<\/li>\n\n\n\n<li><strong>For society<\/strong>, excessive monopoly protection risks <strong>making essential medicines unaffordable<\/strong>, particularly for low-income populations.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>High Cost of Patented Drugs: <\/strong>Patented medicines in India often cost <strong>ten to thirty times more<\/strong> than generic alternatives.\n<ul class=\"wp-block-list\">\n<li><strong>Patent monopolies directly affect affordability and access<\/strong>, especially for chronic and life-threatening diseases like cancer and hepatitis.<\/li>\n\n\n\n<li>As a result, millions of Indians are pushed into <strong>catastrophic health expenditure<\/strong> every year due to high drug costs.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Limited Use of TRIPS Flexibilities: <\/strong>Though TRIPS allows nations to adopt <strong>flexibilities<\/strong> like <strong>compulsory licensing, government use provisions, and parallel imports<\/strong>, India\u2019s use of these tools has been <strong>sporadic and cautious<\/strong>.\n<ul class=\"wp-block-list\">\n<li>Since 2012, only one compulsory license has been granted largely due to <strong>political pressure<\/strong> and <strong>fear of trade retaliation<\/strong> from developed countries.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Pressure from Global Trade Partners: <\/strong>India faces <strong>significant diplomatic and trade pressure<\/strong> from developed nations, especially the United States and the European Union <strong>to strengthen IP enforcement <\/strong>and dilute domestic safeguards and compulsory licensing.\n<ul class=\"wp-block-list\">\n<li>Inclusion of India on the <strong>US Trade Representative\u2019s \u2018Priority Watch List\u2019<\/strong> reflects ongoing scrutiny of its patent practices.<\/li>\n\n\n\n<li>Such external pressures threaten India\u2019s sovereign right to design IP policies suited to its <strong>public health and socio-economic realities<\/strong>.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Weaknesses in Healthcare Infrastructure: <\/strong>It includes inadequate distribution of essential drugs in rural areas, dependence on private healthcare, where drug prices are unregulated, and limited public procurement of patented or life-saving medicines.<\/li>\n\n\n\n<li><strong>R&amp;D and Indigenous Innovation Gaps: <\/strong>Domestic innovation remains underfunded, as India spends less than <strong>1% of its GDP on R&amp;D<\/strong>, compared to over <strong>2.5% in developed countries<\/strong>.<\/li>\n\n\n\n<li><strong>Abuse of Dominant Position: <\/strong>Some patentees engage in <strong>anti-competitive behavior<\/strong>, such as imposing excessive licensing fees; restricting supply chains; and engaging in \u2018patent clustering\u2019 to deter generic entry.\n<ul class=\"wp-block-list\">\n<li>Such practices may violate the <strong>Competition Act, 2002<\/strong>, but enforcement remains limited.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Balancing Public Health and Patent Rights in India<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safeguards Against Evergreening: <\/strong>The <strong>Section 3(d) of the Patents Act<\/strong> prohibits patents on new forms of known substances unless they result in <strong>enhanced therapeutic efficacy<\/strong>.\n<ul class=\"wp-block-list\">\n<li>It prevents pharmaceutical companies from <strong>\u2018evergreening\u2019<\/strong> patents prolonging monopolies through trivial modifications to existing drugs.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Compulsory Licensing: <\/strong>The <strong>government or any interested party <\/strong>can seek a <strong>compulsory license<\/strong> (under <strong>Sections 84 and 92A<\/strong> of the Patents Act) to produce a patented drug without the patentee\u2019s consent if:\n<ul class=\"wp-block-list\">\n<li>The drug is not available at a reasonable price,<\/li>\n\n\n\n<li>The patentee has failed to meet domestic demand, or<\/li>\n\n\n\n<li>It is required for public health or export to countries lacking manufacturing capacity.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Protecting Public Health: <\/strong>India\u2019s Patents Act gives the <strong>central and state governments<\/strong> several powers to safeguard public health:\n<ul class=\"wp-block-list\">\n<li><strong>Section 47(4):<\/strong> Allows the government to use or import patented inventions for public institutions without patentee consent.<\/li>\n\n\n\n<li><strong>Section 66:<\/strong> Permits revocation of a patent if it is \u2018mischievous to the state\u2019 or \u2018prejudicial to the public\u2019.<\/li>\n\n\n\n<li><strong>Section 102:<\/strong> Authorizes the government to acquire a patent in the public interest, compensating the patentee fairly.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Balancing Through Competition Law: <\/strong>The <strong>Competition Act, 2002<\/strong> acts as a complementary mechanism to the Patents Act.\n<ul class=\"wp-block-list\">\n<li>It prohibits <strong>abuse of dominant position<\/strong> and <strong>anti-competitive practices<\/strong> by patent holders.<\/li>\n\n\n\n<li>India promotes both <strong>innovation and affordability<\/strong> by integrating <strong>competition principles<\/strong> with patent law.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Policy Recommendations for a Sustainable Balance<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Formulate a National Patent Policy<\/strong> integrating public health objectives.<\/li>\n\n\n\n<li><strong>Encourage indigenous innovation<\/strong> through state-funded R&amp;D and academic partnerships.<\/li>\n\n\n\n<li><strong>Enhance the use of TRIPS flexibilities<\/strong>, including compulsory licensing in public interest.<\/li>\n\n\n\n<li><strong>Strengthen collaboration<\/strong> between the Patent Office, Drug Controller, and Competition Commission.<\/li>\n\n\n\n<li><strong>Improve drug distribution systems<\/strong>, ensuring rural access to essential patented and generic medicines.\n<ul class=\"wp-block-list\">\n<li>These measures can ensure that intellectual property rights coexist with India\u2019s constitutional commitment to health and welfare.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-background has-fixed-layout\" style=\"background-color:#ebecf0\"><tbody><tr><td><strong>Daily Mains Practice Question<\/strong><br><strong>[Q]<\/strong> Balancing patent protection with the right to public health remains a persistent challenge in India. Examine it in balancing intellectual property rights with the need to safeguard public health.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><a href=\"https:\/\/indianexpress.com\/article\/opinion\/columns\/j-sai-deepak-writes-patent-rights-and-public-health-what-are-bharats-options-10481705\/\" target=\"_blank\" rel=\"noopener\">Source: IE<\/a><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.nextias.com\/ca\/wp-content\/uploads\/2026\/01\/Daily-Editorial-Analysis-20-01-2026.pdf\"><strong>Download PDF<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Published on:<\/strong> 20 January, 2026<\/p>\n<p>India stands at a critical intersection between the enforcement of Intellectual Property Rights (IPRs) and the fulfillment of its public health obligations.<\/p>\n","protected":false},"author":4,"featured_media":64692,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[22],"tags":[],"class_list":["post-64687","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editorial-analysis"],"acf":[],"jetpack_featured_media_url":"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2026\/01\/Editorial-Analysis-900-600.webp","_links":{"self":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/64687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/comments?post=64687"}],"version-history":[{"count":4,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/64687\/revisions"}],"predecessor-version":[{"id":64736,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/64687\/revisions\/64736"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media\/64692"}],"wp:attachment":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media?parent=64687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/categories?post=64687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/tags?post=64687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}